MarketCap
Facebook
X
TelegramQuarterly report 2025-Q3
added 10-31-2025
Illumina Book Value 2011-2026 | ILMN
Book value is a financial metric that reflects the value of a company's assets minus its liabilities as of a specific date, according to accounting records. In simple terms, it is the amount that would remain for the owners of the company if all assets were sold and all debts paid off.What is included in book value
- Assets — all company resources: real estate, equipment, inventory, cash, accounts receivable, and others.
- Liabilities — all debts and financial obligations: loans, accounts payable, taxes, and other obligations.
- Assessment of the company's "real" value
Book value shows how much the company is worth according to accounting data, that is, the value of its property taking debts into account. - Comparison with market capitalization
Comparing book value and the market price of shares helps to understand whether the company is overvalued or undervalued by the market. - Indicator of financial stability
If the book value is high, it indicates the company has significant assets, which reduces risks for investors. - Key component for financial ratios
Many metrics, such as the price-to-book ratio (P/B), use book value to analyze the attractiveness of shares.
Annual Book Value Illumina
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.3 B | 10.1 B | 15.2 B | 7.58 B | - | 4.61 B | 3.76 B | 2.2 B | 1.85 B | - | 1.46 B | 1.53 B | 1.08 B | 1.2 B |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 15.2 B | 1.08 B | 4.74 B |
Quarterly Book Value Illumina
| 2025-Q3 | 2025-Q2 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 6.18 B | 6.09 B | - | 6.08 B | 10 B | 11.8 B | 11.8 B | 12.3 B | - | 15.4 B | 15.3 B | 7.58 B | 15.1 B | 8.68 B | 8.76 B | - | 7.4 B | 7.25 B | 7.26 B | 7.32 B | 7.32 B | 7.32 B | 7.32 B | 6.96 B | 6.96 B | 6.96 B | 6.96 B | 5.26 B | 5.26 B | 5.26 B | 5.26 B | 3.69 B | 4.23 B | 3.99 B | 3.79 B | - | 3.73 B | 3.7 B | 3.5 B | 3.34 B | 3.34 B | 3.34 B | 3.34 B | 3.02 B | 3.02 B | 3.02 B | 3.02 B | 2.57 B | 2.57 B | 2.57 B | 2.57 B | 1.84 B | 2.15 B | 2.26 B | 2.12 B |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 15.4 B | 1.84 B | 6 B |
Book Value of other stocks in the Diagnostics research industry
| Issuer | Book Value | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Centogene N.V.
CNTG
|
77.2 M | - | -6.23 % | $ 30.6 M |  Germany |
 |
Agilent Technologies
A
|
5.39 B | $ 114.84 | -0.55 % | $ 34.9 B |  USA |
 |
Oxford Immunotec Global PLC
OXFD
|
16.7 M | - | - | $ 562 M |  Britain |
|
Akumin
AKU
|
141 M | - | -17.87 % | $ 25.9 M |  Canada |
 |
Burning Rock Biotech Limited
BNR
|
1.85 B | $ 16.3 | 0.62 % | $ 175 M |  China |
 |
Aspira Women's Health
AWH
|
-6.93 M | - | -6.19 % | $ 10.5 M | USA |
 |
Accelerate Diagnostics
AXDX
|
-22.3 M | - | -61.36 % | $ 2.46 M | USA |
 |
Global Cord Blood Corporation
CO
|
4.88 B | - | - | $ 399 M | China |
 |
Fluidigm Corporation
FLDM
|
132 M | - | 1.08 % | $ 308 M | USA |
 |
Genetic Technologies Limited
GENE
|
16.4 M | - | - | $ 7.1 B |  Australia |
 |
Genetron Holdings Limited
GTH
|
548 M | - | 0.12 % | $ 80.1 M | China |
 |
PRA Health Sciences, Inc.
PRAH
|
1.32 B | - | - | $ 10.7 B | USA |
 |
Biocept
BIOC
|
8.86 M | - | -13.05 % | $ 7.29 M | USA |
|
Biodesix
BDSX
|
20.9 M | $ 15.36 | 1.92 % | $ 1.99 B | USA |
 |
Koninklijke Philips N.V.
PHG
|
11 B | $ 27.2 | 0.33 % | $ 20 B |  Niderland |
 |
QIAGEN N.V.
QGEN
|
6.15 B | - | - | $ 10.6 B | Niderland |
 |
CareDx, Inc
CDNA
|
303 M | $ 17.82 | -2.68 % | $ 950 M | USA |
 |
Anixa Biosciences
ANIX
|
14 M | $ 2.59 | 1.57 % | $ 84.1 K | USA |
 |
Biomerica
BMRA
|
4.1 M | $ 2.17 | - | $ 4.98 M | USA |
 |
BioNano Genomics
BNGO
|
44.4 M | $ 1.15 | -4.17 % | $ 6.26 M | USA |
 |
Check-Cap Ltd.
CHEK
|
-1.45 M | - | - | $ 9.42 M |  Israel |
 |
Co-Diagnostics
CODX
|
20.6 M | $ 4.4 | 101.83 % | $ 5.85 M | USA |
 |
Charles River Laboratories International
CRL
|
3.21 B | $ 168.22 | -3.26 % | $ 8.34 B | USA |
 |
Castle Biosciences
CSTL
|
456 M | $ 24.73 | -0.44 % | $ 687 M | USA |
 |
Celcuity
CELC
|
101 M | $ 114.22 | 1.41 % | $ 5.34 B | USA |
 |
Danaher Corporation
DHR
|
83.5 B | $ 192.12 | 0.53 % | $ 137 B | USA |
 |
DermTech
DMTK
|
57.2 M | - | -11.32 % | $ 2.94 M | USA |
 |
DexCom
DXCM
|
2.75 B | $ 63.21 | 1.59 % | $ 24.7 B | USA |
 |
Chembio Diagnostics
CEMI
|
17.8 M | - | 0.22 % | $ 16.8 M | USA |
 |
Enzo Biochem
ENZ
|
56.1 M | - | -8.98 % | $ 14.8 K | USA |
 |
Exact Sciences Corporation
EXAS
|
2.4 B | - | - | $ 19.8 B | USA |
 |
Quest Diagnostics Incorporated
DGX
|
16.2 B | $ 198.96 | 0.91 % | $ 22.1 B | USA |
 |
Fulgent Genetics
FLGT
|
1.13 B | $ 16.42 | -2.38 % | $ 496 M | USA |
 |
Guardant Health
GH
|
-99.3 M | $ 89.66 | -4.44 % | $ 11.2 B | USA |
 |
Heska Corporation
HSKA
|
422 M | - | - | $ 1.31 B | USA |
 |
HTG Molecular Diagnostics
HTGM
|
5.39 M | - | -20.0 % | $ 1.06 M | USA |
 |
ICON Public Limited Company
ICLR
|
9.52 B | $ 109.62 | -4.0 % | $ 9.04 B |  Irlanda |
 |
Interpace Biosciences
IDXG
|
22.4 M | $ 1.97 | 0.63 % | $ 8.72 M | USA |
 |
IQVIA Holdings
IQV
|
6.63 B | $ 170.72 | -1.47 % | $ 29.3 B | USA |
 |
Laboratory Corporation of America Holdings
LH
|
8.64 B | $ 274.46 | 0.27 % | $ 22.8 B | USA |
 |
Lantheus Holdings
LNTH
|
1.09 B | $ 75.89 | -0.28 % | $ 5.12 B | USA |
 |
Medpace Holdings
MEDP
|
459 M | $ 496.0 | -0.47 % | $ 14.3 B | USA |
 |
Motus GI Holdings
MOTS
|
2.69 M | - | -34.28 % | $ 263 K | Israel |
 |
Mettler-Toledo International
MTD
|
-23.6 M | $ 1 266.63 | 0.53 % | $ 26.1 B |  Schweiz |
 |
Myriad Genetics
MYGN
|
368 M | $ 4.67 | -1.68 % | $ 432 M | USA |
 |
ENDRA Life Sciences
NDRA
|
2.26 M | $ 4.74 | 1.07 % | $ 3.73 M | USA |
 |
NeoGenomics
NEO
|
837 M | $ 8.02 | 0.25 % | $ 1.03 B | USA |
 |
Neogen Corporation
NEOG
|
2.07 B | $ 9.56 | 1.59 % | $ 2.07 B | USA |
 |
National Research Corporation
NRC
|
14 M | $ 17.33 | 0.99 % | $ 388 M | USA |